Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
Grossschaedl K, Vallant C, Dernoscheg MT, Richtig M, Öllinger A, Balakirski G, Wilsmann-Theis D, Nguyen VA, Weinlich G, Tsiogka A, Koelblinger P, Scheffel J, Richtig E, Richtig G. Grossschaedl K, et al. Among authors: richtig e. J Dtsch Dermatol Ges. 2023 Nov;21(11):1383-1386. doi: 10.1111/ddg.15199. Epub 2023 Oct 9. J Dtsch Dermatol Ges. 2023. PMID: 37811739 No abstract available.
Coping strategies in melanoma patients.
Trapp M, Trapp EM, Richtig E, Egger JW, Zampetti A, Sampogna F, Rohrer PM, Komericki P, Strimitzer T, Linder MD. Trapp M, et al. Among authors: richtig e. Acta Derm Venereol. 2012 Nov;92(6):598-602. doi: 10.2340/00015555-1351. Acta Derm Venereol. 2012. PMID: 22772950 Free article.
Interferon for melanoma.
Richtig E, Langmann G. Richtig E, et al. Ophthalmology. 2010 Sep;117(9):1861. doi: 10.1016/j.ophtha.2010.03.074. Ophthalmology. 2010. PMID: 20816255 No abstract available.
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM, Robert C, Richtig E, Miller WH Jr, Masucci GV, Walpole E, Lebbe C, Steven N, Middleton MR, Hille D, Zhou W, Ibrahim N, Cebon J. Petrella TM, et al. Among authors: richtig e. Eur J Cancer. 2017 Nov;86:115-124. doi: 10.1016/j.ejca.2017.08.032. Epub 2017 Oct 4. Eur J Cancer. 2017. PMID: 28987768 Free article. Clinical Trial.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbè C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Gonzales Cao M, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Curvietto M, Melero I, Palmieri G, Grimaldi AM, Giannarelli D, Dummer R, Chiarion Sileni V. Ascierto PA, et al. Among authors: richtig e. J Clin Oncol. 2023 Jan 10;41(2):212-221. doi: 10.1200/JCO.21.02961. Epub 2022 Sep 1. J Clin Oncol. 2023. PMID: 36049147 Clinical Trial.
139 results